Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF
Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
get now
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF
Pro members get actionable news alerts up to 30 minutes before other traders — Get our lowest prices
get now
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Robyn Karnauskas
Amgen Wins Big With FDA, Analyst Sees Soaring Potential
Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4
Gilead Sciences Outlook Brightens; Citi Upgrades
Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4
Gilead Sciences Outlook Brightens; Citi Upgrades
Wall Street Reacts To Celgene's Reported Interest In Juno
Citi Downgrades Regeneron, Citing 'Underappreciated' Risk
Wall Street Reacts To Celgene's Reported Interest In Juno
Citi Downgrades Regeneron, Citing 'Underappreciated' Risk
Biogen Bull Thesis Baked In, No Longer A Buy At Citi
What To Do With Celgene Now With Major Catalysts Gone
Read More...
Robyn Karnauskas Recent News
A Decade Of Sales Growth Lies Ahead For Vertex Pharmaceuticals
Bluebird News A Positive For Juno, Kite Pharma
Citi Starts Calithera Biosciences At Sell On Cash Burn And Lack Of Near-Term Catalysts
Citi Launches Positive Coverage On Five Prime Therapeutics
Citi Sees 26% Upside In TESARO On The Strength Of Trial Data
Citi Sees Kadmon's Trials As 'Risky,' Initiates With Neutral Rating
Citigroup Upgrades Bellicum Pharma, Sees Clearer Pathway For BPX-501 Approval
Citi Raises TESARO Price Target 38%, Sees 16.3% Upside
Alexion Pharma Brexit Selloff Creates An Entry Point: Trading At 'Dark-Sky' Valuation
Regeneron CEO And CFO Met With Citi: Here Are The Takeaways
Lingo Failure Leads Citi To Downgrade Biogen
Solid Potential For Gilead To Beat Estimates And Raise Guidance: Here's How
Has A Biotech Recovery Started Yet?
Citi Surprised, Confused Amid Report Biogen May Divest Hemophilia Unit
Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover
Wall Street's Best Think Gilead Will Continue To Outperform The Market
Wall Street Mixed On Biogen Before Earnings
Deutsche Bank Bullish On Biogen: New Data Doesn't Change Probability Of Success For Alzheimer's
BioMarin's Results Are In: What Do They Mean?
Deutsche Sees Cancer Treatment Home Run At Infinity Pharmaceuticals
This Data Offers Insight Into Gilead Sales
Gilead Alert: What Deutsche Bank Is Saying
Why BioMarin Pharmaceutical Is Surging